Covalon Technologies Ltd. (CVALF)
| Market Cap | 82.83M +95.1% |
| Revenue (ttm) | 24.19M +4.1% |
| Net Income | 3.09M +89.7% |
| EPS | 0.11 +84.9% |
| Shares Out | n/a |
| PE Ratio | 26.81 |
| Forward PE | 21.00 |
| Dividend | 0.11 (3.57%) |
| Ex-Dividend Date | Nov 4, 2025 |
| Volume | 66,426 |
| Open | 2.925 |
| Previous Close | 2.871 |
| Day's Range | 2.904 - 3.000 |
| 52-Week Range | 1.160 - 3.000 |
| Beta | 0.14 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 16, 2026 |
About Covalon Technologies
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company’s platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secon... [Read more]
Financial Performance
In fiscal year 2025, Covalon Technologies's revenue was 32.82 million, an increase of 5.29% compared to the previous year's 31.17 million. Earnings were 2.06 million, a decrease of -22.91%.
Financial numbers in CAD Financial StatementsNews
Covalon Reports Encouraging Findings From Real World Evidence Analysis Comparing Collagen Dressings
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced encouraging findings ...
Covalon to Present at the 2026 Annual Smallcap Discoveries Conference After Reporting Revenue Growth of 20% and Gross Margin of 67%
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company today announced that it will present a...
Covalon Technologies Ltd Q3 Earnings Summary
(RTTNews) - Below are the earnings highlights for Covalon Technologies Ltd (COV.V):
Covalon Technologies Earnings Call Transcript: Q3 2026
Q3 saw 20% revenue growth and record profitability, driven by U.S. vascular access and contamination protection solutions. Gross margin exceeded 67%, net income surged, and cash flow enabled both a dividend and capital investment. Management remains optimistic for continued growth.
Covalon Technologies Earnings release: Q3 2026
Covalon Technologies released its Q3 2026 earnings on August 27, 2026, summarizing the period's financial results.
Covalon Technologies Registration statement: Q3 2026
Covalon Technologies filed a registration statement on August 27, 2026, providing details about a securities offering with the SEC.
Covalon Technologies Registration statement: Q3 2026
Covalon Technologies filed a registration statement on August 27, 2026, providing details about a securities offering with the SEC.
Covalon Technologies Slides: Q3 2026
Covalon Technologies has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 27, 2026.
Covalon Reports Fiscal 2026 Third Quarter Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 third...
Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2026 Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2026 resul...
Covalon Announces Appointment of New Director and DSU Grants
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the appointment of Dr...
Covalon Technologies Earnings Call Transcript: Q2 2026
Q2 delivered strong revenue and margin growth, with adjusted EBITDA more than doubling year-over-year. Adoption of contamination prevention products is accelerating at leading hospitals, and management expects a robust second half with continued operating leverage.
Covalon Technologies Slides: Q2 2026
Covalon Technologies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 21, 2026.
Covalon Technologies Registration statement: Q2 2026
Covalon Technologies filed a registration statement on May 21, 2026, providing details about a securities offering with the SEC.
Covalon Technologies Registration statement: Q2 2026
Covalon Technologies filed a registration statement on May 21, 2026, providing details about a securities offering with the SEC.
Covalon Technologies Earnings release: Q2 2026
Covalon Technologies released its Q2 2026 earnings on May 21, 2026, summarizing the period's financial results.
Covalon Reports 2026 Second Quarter Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 secon...
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 resul...
Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (TSX: COV; OTCQX: CVALF), an advanced medical technologies company, today announced a series of important milestones reflecting the Com...
Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its upcoming presence at the Infusion Nurses Socie...
Covalon Announces Grant of Deferred Share Units
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the Company has gr...
Covalon Announces Voting Results from Fiscal 2025 Annual General and Special Meeting of Shareholders
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the ma...
Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 25, 2026
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the annual meeting...
Covalon Technologies Earnings Call Transcript: Q1 2026
Q1 revenue declined year-over-year, but gross margins remained strong and Q2 is already outperforming Q1. Major new hospital wins, strong customer retention, and investments in automation and IT are driving optimism for robust growth in fiscal 2026.
Covalon Technologies Earnings release: Q1 2026
Covalon Technologies released its Q1 2026 earnings on February 25, 2026, summarizing the period's financial results.